Targeting aENaC with an epithelial RNAi trigger delivery platform for the treatment of cystic fibrosis

E. Bush (Madison, WI, United States of America), A. Nicholas (Madison, WI, United States of America), T. Pei (Madison, WI, United States of America), I. Kuipers (Madison, WI, United States of America), W. Cheng (Madison, WI, United States of America), H. Hamilton (Madison, WI, United States of America), J. Hegge (Madison, WI, United States of America), X. Li (Madison, WI, United States of America), A. Glebocka (Madison, WI, United States of America), R. Zhu (Madison, WI, United States of America), B. Chen (Madison, WI, United States of America), P. Kuehl (Albuquerque, NM, United States of America), T. Schluep (Madison, WI, United States of America), Z. Li (Madison, WI, United States of America)

Source: International Congress 2018 – Cystic fibrosis: microbiological aspects and new treatments
Session: Cystic fibrosis: microbiological aspects and new treatments
Session type: Oral Presentation
Number: 514
Disease area: Paediatric lung diseases

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
E. Bush (Madison, WI, United States of America), A. Nicholas (Madison, WI, United States of America), T. Pei (Madison, WI, United States of America), I. Kuipers (Madison, WI, United States of America), W. Cheng (Madison, WI, United States of America), H. Hamilton (Madison, WI, United States of America), J. Hegge (Madison, WI, United States of America), X. Li (Madison, WI, United States of America), A. Glebocka (Madison, WI, United States of America), R. Zhu (Madison, WI, United States of America), B. Chen (Madison, WI, United States of America), P. Kuehl (Albuquerque, NM, United States of America), T. Schluep (Madison, WI, United States of America), Z. Li (Madison, WI, United States of America). Targeting aENaC with an epithelial RNAi trigger delivery platform for the treatment of cystic fibrosis. 514

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology
Source: Annual Congress 2012 - Molecular biology of pro- and anti-inflammatory responses in the lung
Year: 2012

Targeting CFTR as a therapy for cystic fibrosis
Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung
Year: 2010

Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis
Source: Eur Respir J, 57 (1) 1902426; 10.1183/13993003.02426-2019
Year: 2021



Potential therapeutic use of 12-Lipoxygenase inhibitors in the treatment of mucus overproduction in cystic fibrosis
Source: Research Seminar 2009 - Molecular and Cellular aspects of Chronic Lung Disease
Year: 2009

Measuring CFTR function in respiratory epithelial cell cultures: step to individualize treatments in cystic fibrosis?
Source: Virtual Congress 2021 – Monitoring of lung disease and CFTR function in children with cystic fibrosis
Year: 2021

Do characteristic airway epithelial change precede the development of lung fibrosis? Ectopic epithelial marker protein expression in bleomycin induced fibrosis replicates that seen in bronchiolized epithelium in IPF
Source: Annual Congress 2012 - Cell culture and animal models of lung disease
Year: 2012

Targeting cystic fibrosis inflammation in the age of CFTR modulators: focus on macrophages
Source: Eur Respir J, 57 (6) 2003502; 10.1183/13993003.03502-2020
Year: 2021



How organoids helped to discover cystic fibrosis transmembrane conductance regulator (CFTR) therapeutics and predict response to treatment
Source: International Congress 2016 – Closing the gap: novel translational research strategies
Year: 2016


Gene therapy for cystic fibrosis: successes and challenges
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=79
Year: 2006

Pulmonary surfactant as drug delivery system to target lung epithelium: new approach for the treatment of epithelial injury after bleomycin challenge
Source: International Congress 2018 – Regenerative and anti-fibrotic approaches
Year: 2018

Expression of the nuclear factor-?B inhibitor A20 is altered in the cystic fibrosis epithelium
Source: Eur Respir J 2013; 41: 1315-1323
Year: 2013



ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies
Source: Eur Respir J, 56 (6) 2000946; 10.1183/13993003.00946-2020
Year: 2020



Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties via hydration
Source: Eur Respir J, 59 (2) 2100185; 10.1183/13993003.00185-2021
Year: 2022



Peptide transport mechanisms in cystic fibrosis and normal human lung
Source: Eur Respir J 2001; 18: Suppl. 33, 76s
Year: 2001

Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells
Source: Eur Respir J 2015; 45: 428-439
Year: 2015



The cystic fibrosis airway milieu enhances rescue of F508del in a pre-clinical model
Source: Eur Respir J, 52 (6) 1801133; 10.1183/13993003.01133-2018
Year: 2018



Epithelial cell regulation of immunity in cystic fibrosis
Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new basic and clinical physiology research
Year: 2012